Pacira BioSciences (PCRX) Projected to Post Quarterly Earnings on Thursday

Pacira BioSciences (NASDAQ:PCRX) is expected to be releasing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Pacira BioSciences to announce earnings of $0.7320 per share and revenue of $182.87 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.

Pacira BioSciences (NASDAQ:PCRX) last issued its earnings results on Tuesday, August 4th. The company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.08. Pacira BioSciences had a net margin of 1.96% and a return on equity of 9.68%. The business had revenue of $192.40 million during the quarter, compared to analysts’ expectations of $191.06 million. During the same quarter in the prior year, the business posted $0.74 EPS. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. On average, analysts expect Pacira BioSciences to post $1.86 EPS for the current fiscal year and $2.37 EPS for the next fiscal year.

Pacira BioSciences Stock Down 0.0%

NASDAQ:PCRX traded down $0.01 during midday trading on Tuesday, hitting $36.40. 76,640 shares of the company were exchanged, compared to its average volume of 855,212. The company has a fifty day simple moving average of $29.30 and a 200 day simple moving average of $24.89. Pacira BioSciences has a fifty-two week low of $18.80 and a fifty-two week high of $36.67. The company has a current ratio of 5.04, a quick ratio of 3.94 and a debt-to-equity ratio of 0.54. The company has a market capitalization of $1.45 billion, a PE ratio of 103.99 and a beta of 0.25.

Insiders Place Their Bets

In related news, SVP Lauren Riker sold 6,000 shares of the company’s stock in a transaction on Thursday, October 8th. The shares were sold at an average price of $36.32, for a total value of $217,920.00. Following the completion of the sale, the senior vice president owned 62,284 shares in the company, valued at $2,262,154.88. This represents a 8.79% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jonathan Slonin sold 3,040 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $23.23, for a total transaction of $70,619.20. Following the completion of the sale, the insider owned 216,384 shares of the company’s stock, valued at approximately $5,026,600.32. This trade represents a 1.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.40% of the company’s stock.

Wall Street Analysts Forecast Growth

PCRX has been the topic of several research reports. Needham & Company LLC lowered Pacira BioSciences from a “buy” rating to a “hold” rating in a report on Thursday, October 8th. Truist Financial cut Pacira BioSciences from a “buy” rating to a “hold” rating and lifted their target price for the stock from $31.00 to $36.50 in a research report on Friday, October 9th. Leerink Partners started coverage on Pacira BioSciences in a report on Wednesday, September 9th. They issued a “market perform” rating and a $28.00 target price for the company. Jefferies Financial Group downgraded Pacira BioSciences from a “buy” rating to a “hold” rating and set a $36.00 target price for the company. in a report on Thursday, October 8th. Finally, JPMorgan Chase & Co. raised Pacira BioSciences from an “underweight” rating to a “neutral” rating and set a $36.50 target price for the company in a research report on Thursday, October 8th. One analyst has rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $33.33.

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain-management and regenerative health solutions. The company’s products are designed to address acute postsurgical pain and osteoarthritis-related pain while supporting efforts to reduce reliance on opioid medications.

Pacira’s lead product is EXPAREL, an extended-release formulation of bupivacaine administered by injection for postsurgical pain management. The company also markets ZILRETTA, an extended-release corticosteroid injection indicated for osteoarthritis knee pain, and iovera°, a cryoanalgesia system that uses controlled cooling to temporarily block peripheral nerves and relieve pain.

Formerly known as Pacira Pharmaceuticals, the company adopted the Pacira BioSciences name to reflect its broader focus on innovative pain and regenerative-health therapies.